Stada Group
Patrick Genestin is a seasoned executive with extensive experience in business development and strategic leadership within the pharmaceutical industry. Currently serving as Chief Business Officer at Stada Corp, Patrick has held significant roles including Chief Business Officer at 1910 Genetics and Vice President of Business Development and Pipeline Strategy at Hikma Pharmaceuticals. Prior experience includes various leadership positions at Novartis, such as VP of Business Development and Licensing for North America at Sandoz and Sr. Director of Business Development, Strategic Licensing and Acquisitions. Patrick began their career as Manager of Business Development and also served as Finance Manager for Global Commercial Operations at CSL Behring. Educational credentials include studies at The Wharton School and Penn State University.
This person is not in any offices
Stada Group
14 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.